Dopamine responsiveness of human prolactinoma cells as determined by the reverse hemolytic plaque assay

The responsiveness in vivo to dopamine of prolactin (PRL) secretion in patients with prolactinoma was compared with that in vitro of single cells obtained from the same prolactinomas by surgical operations. Six patients with prolactinoma showing various degrees of hyperprolactinemia were challenged by bromocriptine suppression test (2.5 mg, peroral) before operation. Bromocriptine administration caused a decrease in the serum PRL concentration ranging 24-95% and there was no correlation between the basal PRL level and bromocriptine-induced inhibition. Monodispersed pituitary cells obtained from the prolactinomas by operation were subjected to a reverse hemolytic plaque assay for PRL to determine PRL secretion at the single cell level under basal conditions as well as in response to dopamine. The percentage of plaque-forming cells under basal conditions ranged 15-55% among the prolactinomas. The percentage of plaque-forming cells and plaque area were decreased in a dose-dependent manner by 10(-7) - 10(-5) M dopamine for the pituitary cells obtained from some adenomas but not for those from other adenomas. When the inhibition rates in vitro due to 10(-5) M dopamine in these two parameters were compared with the inhibition rate in vivo in the serum PRL concentration due to bromocriptine, it was found that there was a significant correlation between them. These results show that the reverse hemolytic plaque assay can be used to determine in vitro responsiveness to dopamine of PRL secretion from single prolactinoma cells.(ABSTRACT TRUNCATED AT 250 WORDS)